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Introduction This thesis is a summary of a manuscript submitted to the Journal of Forensic Toxicology in February 2019.
New synthetic cannabinoids (SCs) are being constantly introduced into the clandestine market to evade detection by law enforcement and researchers. As a result, analytical labs often do not have access to reference mass spectra for newer cannabinoids, let alone access to reference standards for the parent or metabolites. The extensive metabolism of parent compounds make detection in body fluids challenging, but in vitro studies can elucidate marker metabolites.
The primary goal of this work was to calculate half-life, clearance and to identify metabolites to the extent possible of three previously uncharacterized SCs. Human liver microsomes, an affordable in vitro alternative for drug biotransformation and pharmacokinetics studies was utilized for this purpose. Microsomes are rich in cytochrome P450 (CYP) enzymes responsible for the metabolism of most drugs.
The three synthetic cannabinoids used in this study, N-(1-amino-1-oxo-3-phenylpropan- The structures of the 15 metabolites useful in toxicology analysis were tentatively identified using high resolution mass spectrometry (HRMS), whereas half-life and clearance were investigated using a triple quadrupole system.
Literature Review
Preface Synthetic Cannabinoids are a class of novel psychoactive substances (NPS) which are used for their psychoactive effects [1] . Whenever a NPS is scheduled the structure is easily modified so that it goes undetected by Law Enforcement [2] . Toxicologists are faced with the challenge of identifying NPS as they have become prevalent [3, 4] and are usually extensively metabolized [5] . This makes it difficult to know the parent compound which was consumed. For this reason, it is important to study the metabolism of such emerging compounds. Identifying marker metabolites can help Forensic Toxicologists propose which NPS might have been consumed [6] .
SC Effects
Cannabinoid psychotropic effects have been found to be mediated through the G-coupled CB1 and CB2 receptors [7] . CB1 receptors are found in neurons of the central nervous system whilst CB2 receptors are localized in tissues of the immune system [7] . Cannabinoid consumption results in CB1 receptor mediated inhibition of synaptic transmission [8, 9] which can lead to mood changes, affecting pain perception, temperature regulation, sleep, and the cardiovascular system [10, 11] . This is important because synthetic cannabinoids have been shown to have a high affinity for either the CB1 or the CB2 receptors [12, 13] which can prolong the effects on consumers. In a survey of 50 patients conducted by Hermanns-Clausen et al. the duration of symptoms from synthetic cannabinoids lasted from one hour to more than 24 hours [11] .
Classes of SCs
SCs were previously classified by structure and were divided into seven major groups:
naphthoylindoles (e.g. JWH-018), naphthylmethylindoles (e.g. JWH-175), naphthylmethylindenes (e.g. JWH-176), naphthoylpyrroles (e.g. JWH-307), phenylacetylindoles (e.g. JWH-250), cyclohexylphenols (e.g. CP 47,497), and classical cannabinoids (e.g. HU-210) [14] . An example of each class in comparison to Δ 9 -THC is shown in Figure 1 . Constant modification of these compounds made this classification system obsolete. Instead of naming SCs after the inventor of the compound, researchers now use key components of the structure.
These components include the core, linker, linked group and tail[15] as shown in Figure 2 . Code names can be derived from the chemical names. For example, the code name for N-(1-
The SCs used in this study is shown in Figure 2 . PX2 has been declared a hazardous or illegal substance in Sweden amongst other countries [16] . PX1 and PX2 were declared dangerous substances by the Louisiana Legislature in 2015, and was based upon the substances high potential for abuse, lack of medical use in the United States, no accepted safety for use under medical supervision, and hazard to the health and safety of the Louisiana residents [17] .
The binding affinity of PX1 is 485±117 and 164±17 nM at the CB1 and CB2 receptors respectively [18] . The binding affinity of PX2 is 127±43 and 17.4±1.4 nM at the CB1 and CB2 receptors respectively [18] . The binding affinity of (S)APP-CHMINACA at the CB1 receptor is 251 nM and 8.09 nM at the CB2 receptor with a selective index of 31.0 [19] . Doi et al reported the binding affinity of (R)APP-CHMINACA as 33.7 µM and 190 nM at the CB1 and CB2 receptors respectively, with a selective index of 68.8 making (S)APP-CHMINACA more potent.
As shown in Figure 2 , although similar in structure, PX1 has an indole core whereas PX2 has an indazole core. Similar to PX2, PX3 has an indazole core but a cyclohexylmethyl tail.
These differences are enough for each to be categorized separately. The PINACA class has an npentyl tail, indazole core, carboxamide linker but varying linked groups. The CHMINACA class has a cyclohexylmethyl tail, indazole core, carboxamide linker but varying linked groups. PICA classes contain an indole core, n-pentyl tail, carboxamide linker and varying linked groups. 
Models for Metabolite Identification
In vitro studies which elucidate marker metabolites have been performed using human liver microsomes and hepatocytes [20] . Hepatocytes contain uptake and efflux transporters for the movement of drugs across cell membranes [21] and the necessary enzymes and co-factors for drug metabolism in concentrations similar to the liver, thereby close to in vivo conditions [22] . However, they are expensive, not readily available, preparations can only be used once [22, 23] , and they have limited viability [24] . Human liver microsomes offer an affordable alternative. It is a well characterized in vitro model which retains enzyme activity for many years when frozen at −80℃ [24] . Drug biotransformation and pharmacokinetics data such as half-life and clearance can be derived from microsomal models [25] , [26] . The time taken for the concentration of a drug to decrease by half is called its half-life. Intrinsic clearance is the assessment of the liver's activity towards a drug and can be used to confirm metabolism as the major route of drug clearance [27, 28] . Microsomal clearance can be scaled to calculate liver and hepatic clearance thereby increasing understanding of in vivo conditions. Although half-life and clearance are important parameters used for drug discovery and dosing regimens, they are equally useful in forensic testing as they can indicate if the parent drug or metabolite is a better proposition for drug consumption. A drug's structure can be useful in determining the extent of metabolism.
Studies have shown that lipophilic drugs have greater clearance and therefore undergo extensive first pass metabolism [29] [30] [31] , [32] .
Drug metabolizing enzymes are classified as phase I and phase II. Phase I enzymes consist of the cytochrome P450 (CYP) superfamily of microsomal enzymes found in the liver, lungs, kidneys and gastrointestinal tract [33] and play a crucial role in drug metabolism [34] .
Phase II enzymes include sulfotransferases [35] , UDP-glucoronosyltransferases, epoxide hydrolases, glutathione S-transferases and N-acetyltransferases among others. Drugs are generally conjugated during phase II metabolism and are made more hydrophilic to enhance excretion in urine [33] . During phase I, drugs are modified through hydrolysis, oxidation, and reduction [20] therefore enabling further conjugation during phase II. Although microsomes lack phase II enzymes, they are rich in cytochrome P450 (CYP) enzymes [36] , [37] , [38] . This enables the detection of metabolites prior conjugation in phase II.
In silico studies may be conducted to predict metabolites of uncharacterized novel psychoactive substances. A knowledge of the solubility of the drug can help predict how it interacts with other molecules in a particular environment and therefore the transformations it may undergo [39] . In this study Compound Discoverer ® was used to elucidate metabolism mainly through phase I metabolism due to the limited phase II enzymes present in liver microsomes. 
Materials and Methods

PX
Metabolite Identification
Microsome incubation procedure was adapted from previous studies [41] . Data was acquired using Full MS and ddMS 2 using the optimized parameters in Table 2 .
Compound Discoverer v2.1.0.401 (ThermoFisher Scientific ® ) was used for elucidation of metabolite profiling and Thermo XCalibur™ v2.2 (ThermoFisher Scientific ® ) to verify mass spectra. The workflow from Compound Discoverer is shown in Appendix 1. The phase I transformations for NM2201, PX-1 and PX-2 included dehydration, desaturation, hydration, nitro reduction, oxidation, oxidative deamination to alcohol and ketone, oxidative defluorination, reduction, and reductive defluorination whereas no fluorine transformations were selected for PX-3 as it has no fluorine in its structure. Glucuronide conjugation was the only phase II transformation assessed. Dealkylation and dearylation were applied for a maximum of two steps utilizing a minimum mass of 150 Da. Mass tolerance was set to 5 ppm. The experiment was duplicated. 
Results and Discussion Method Validation
Bias was less than ±20% for all compounds. All analytes were within ±20% ionization suppression/enhancement at 25.0 ng/mL and 100.0 ng/mL except 5FPB22 metabolite which was 27% at low range and 23% at the high range. This was acceptable as 5FPB22 metabolite was used qualitatively. The correlation coefficient for within and between injection variability were 0.999 and 1.000 for all analytes respectively. Between-run and within-run %CV were within ±10%. The estimated LOD was 0.4, 0.6, 0.3, 0.3, and 1.8 ppb for PX-1, PX-2, PX-3, NM2201, and 5FPB22 metabolite respectively. No carryover was observed.
Metabolic Stability
Clearance was determined using the natural logarithm of the drug/ internal standard ratio. [27] .
where [V ] is the incubation volume in mL and [P] is the amount of microsomal protein in the incubation. Table 3 minutes and in vitro clearance as 0.088 mL/min/mg for NM2201 [42] . The calculated half-lives for PX-1, PX-2 and PX-3 were 15.1 ± 1.02, 3.4 ± 0.27, and 5.2 ± 0.89 respectively as shown in Table 3 . Plots of the half-life data is shown in Appendix 1. PX-1 showed the lowest clearance rate, 0.046 mL/min/mg whereas PX-2 had the highest clearance rate, 0.202 mL/min/mg. Drugs may be excreted in urine unchanged or chemically modified to facilitate excretion. In this study, a higher clearance rate was expected for the more polar PX-1 but the lack of phase II enzymes may have limited clearance. PX-2 and PX-1 were expected to have comparable clearance rates due to structural similarities. The difference in the observed values may have been due to an extra nitrogen atom in PX-2 which made it less polar, but sufficiently metabolized by CYP450 enzymes to facilitate excretion. However, the results indicate that the SCs are all extensively metabolized.
A survey of the literature yielded binding affinities, clearance and half-life data for SCs structurally similar to the ones investigated in this study ( Table 3 ). In this study, PX-1, PX-2 and PX-3 were compared to other PICA, PINACA and CHMINACA SCs respectively, where the only difference was the linked group. Although there is limited half-life and clearance data, PX-1 showed the lowest clearance rate in the PICA class and was the least potent based on Ki values.
It is possible the phenylalaninamide component of PX-1 increases its polarity more than 5F-CUMYLPICA and STS-135 which require higher clearance. However, further investigations for amide containing PICA SCs such as 5F-ADBICA, 5F-AB-PICA and 5F-SDB-006 are required to support these observations. Although PX-2 is the least potent PINACA, it is not the least cleared. A similar trend to PX-1 is expected but would require further investigations. No data was available for other CHMINACA SCs, but low polarity compounds may show higher clearance in vitro. A class comparison of half-life and clearance data can provide useful information about emerging compounds in that class. Table 3 : Half-life, clearance and Ki summary for selective SC structurally related to PX-1, PX-2, PX-3.
Drug (mins)
,
(mL/min/mg) Ki at CB1 (nM) Ki at CB2 (nM)
PICA 5F-CUMYL-PICA 1.77 [43] 0.39 [43] 1.37 ± 0.26 [18] 29.1 ± 2.4 [18] STS-135 3.1 ± 0.2 [44] 0.222 [44] 2.51 ± 0.35 [45] 0.794 ± 0.071 [45] 5F-ADBICA N/A N/A 2.72 ± 0.35 [18] 1.83 ± 0.11 [18] 5F-MDMB-PICA N/A N/A 9.35 ± 0.07 [46] 8.13 ± 0.05 [46] 5F-MMB-PICA N/A N/A 15.2 ± 5.0 [18] 19.8 ± 4.2 [18] 5F-AB-PICA N/A N/A 35 ± 7.7 [18] 89.0 ± 33.2 [18] 5F-SDB-006 N/A N/A 71.9 ± 13.5 [45] 430 ± 73 [45] PX-1 (APP-PICA) 15.1 ± 1.02 0.046 485 ± 117 [18] 164 ± 17 [18] PINACA 5F-AMB 1.0 ± 0.2 [47] 0.67 [47] 1.13 ± 0.48 [18] 1.38 ± 0.22 [18] 5F-ADB-PINACA N/A N/A 1.43 ± 0.69 [18] 0.694 ± 0.078 [18] 5F-APINACA N/A N/A 1.94 ± 0.55 [45] 0.266 ± 0.041 [45] 5F-AB-PINACA 35.9 ± 3.0 [48] 0.019 [48] 4.96 ± 1.37 [18] 3.77 ± 0.25 [18] 5F-ADB N/A N/A 23.3 ± 10.2 [18] 5.99 ± 2.47 [18] PX-2 (APP-PINACA) 3.4 ± 0.27 0.202 127 ± 43 [18] 17.4 ± 1.4 [18] CHMINACA MDMB-CHMINACA N/A N/A 0.135 ± 0.028 [18] 0.222 ± 0.034 [18] MAB-CHMINACA N/A N/A 0.333 ± 0.059 [18] 0.331 ± 0.048 [18] MA-CHMINACA N/A N/A 0.339 ± 0.073 [18] 0.301 ± 0.092 [18] AB-CHMINACA N/A N/A 1.72 ± 0.14 [18] 0.78 ± 0.11 [49] 1.91 ± 0.20 [18] 0.45 ± 0.03 [49] PX-3 (APP-CHMINACA)
5.2 ± 0.89 0.133 (R) 33.7 µM [19] (S) 251 [19] 9.81 ± 4.56 [18] (R) 190 [19] (S) 8.09 [19] 4.39 ± 0.59 [18] Metabolite Identification
PX-1 Metabolic Pathway
The four proposed phase I metabolites of PX-1 in this study, are shown in Figure 3 .
Oxidation was the common route of biotransformation for all PX-1 metabolites. SRF-3 ((1-(5fluoropentyl)-1H-indole-3-carbonyl)phenylalanine), was the only fluorinated metabolite detected and eluted later than PX-1 despite containing more oxygen atoms. Although metabolites are usually more hydrophilic than parent compounds to facilitate excretion, in this study less polar metabolites were observed possibly because phase II enzymes were lacking. The clearance rate of PX-1 suggest conjugation as a dominant biotransformation pathway. A summary of the retention times and diagnostic ions is shown in Table 4 and chromatograms are shown in Appendix 1.
As shown in Figure 4 Table 5 . Chromatograms of PX-2 and metabolites are shown in Appendix 1.
PX-2 Metabolic Pathway
PX-2 and the major metabolite FU-1 shared the same diagnostic ions as shown in Figure   5 . a similar effect on its hydrophilicity. As shown by the retention times in Table 6 , APP-1 was least polar whereas the hydroxylated metabolites eluted first. Appendix 1 shows the chromatogram of PX-3 and metabolites. 
PX-3 Metabolic Pathway
Suggested marker metabolites
SRF-1 can be considered a marker metabolite because it was the most abundant PX-1 metabolite and is sufficiently polar. SRF-2, the second most abundant metabolite of PX-1 is a good target because it was the most polar of the detected metabolites. FU-1 and APP-1 were the major metabolites of PX-2 and PX-3 respectively, and while good marker metabolites further transformation may occur to increase elimination. FU-2 and APP-2 are also likely marker metabolites which may be detected in urine. The detected metabolites for the targeted compounds did not overlap with each other's proposed metabolic pathway or previously characterized SCs of the same class. However, similarities in diagnostic ions were observed.
Two common fragments m/z 144 and m/z 232 observed in PX-1 and similar PICA SCs are characteristic of the indole core and fluoropentyl tail [43, 44, 50] . The fragments m/z 145, 233, and 213 were observed in the elucidation of PX-2 and other PINACA compounds and are characteristic of the indazole core and fluoropentyl tail [47, 48, 51, 52] . The most common fragments m/z 145, 257, and 241 observed in PX-3 and other CHMINACA SCs are characteristic of the indazole core and cyclohexylmethyl tail. These observations suggest fragments corresponding to the core of SCs may be insufficient for confirmation and therefore require fragments with the core and parts of the tail or linked group.
Conclusion
Potent synthetic cannabinoids are constantly emerging on the black market. Studies have shown these substances to undergo extensive biotransformation thus making parent compounds challenging to detect by existing methods. However, in vitro studies are useful in identifying potential marker metabolites.
The observations in this study suggest the metabolic pathways of PX-1, PX-2 and PX-3 do not overlap. Four, six, and five metabolites of PX-1, PX-2 and PX-3 respectively, were detected and their structures elucidated. Oxidation was the common biotransformation between compounds and the major metabolite of PX-1 was transformed through oxidative defluorination whereas PX-2 and PX-3, through oxidative deamination. SRF-1, SRF-2, FU-1, FU-2, APP-1 and APP-2 are promising marker metabolites. This work showed PX-1 had the highest half-life (15.1 ± 1.02 mins) and subsequently the lowest clearance (0.046 mL/min/mg) whereas PX-2 had the highest clearance (0.202 mL/min/mg). Comparison of available clearance data for similar compounds indicate functional groups which reduce polarity have higher clearance rates, but further research is required to support this hypothesis. Standards for marker metabolites and in vivo studies can confirm observations in this study and could therefore include the metabolites in toxicology screens.
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